Stockscreener 앱 받기
169.41
1.02%
-1.75
전일 마감가:
$171.16
열려 있는:
$170.62
하루 거래량:
1.09M
Relative Volume:
0.96
시가총액:
$10.29B
수익:
$4.09B
순이익/손실:
$-404.84M
주가수익비율:
-25.11
EPS:
-6.7469
순현금흐름:
$1.24B
1주 성능:
+5.14%
1개월 성능:
-0.19%
6개월 성능:
+45.94%
1년 성능:
+38.16%
1일 변동 폭
$167.52
$172.59
1주일 범위
$159.35
$173.09
52주 변동 폭
$95.49
$182.99
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
명칭
Jazz Pharmaceuticals Plc
전화
353-1-634-7800
주소
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
JAZZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
169.41 | 10.40B | 4.09B | -404.84M | 1.24B | -6.7469 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-15 | 개시 | Deutsche Bank | Buy |
| 2025-03-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Buy |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-11-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-29 | 개시 | Raymond James | Mkt Perform |
| 2023-06-12 | 재개 | Wells Fargo | Equal Weight |
| 2022-12-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-11-19 | 재개 | Goldman | Buy |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-10-05 | 개시 | Citigroup | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-05-19 | 재개 | JP Morgan | Overweight |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 개시 | Jefferies | Buy |
| 2020-03-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Neutral |
| 2019-08-21 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Peer Perform |
| 2018-11-08 | 재확인 | B. Riley FBR | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 재확인 | H.C. Wainwright | Neutral |
| 2018-03-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Is Jazz (JAZZ) Quietly Recasting Its Oncology Strategy Through HER2 Partnerships And Voucher Monetization? - simplywall.st
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug - MSN
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Momentum - simplywall.st
JPM26: Jazz sells PRV for $200m, targets deals in 2026 - Pharmaceutical Technology
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Languishes in Senate - BioSpace
Jazz Pharmaceuticals stock rating reiterated at Outperform by RBC Capital - Investing.com Nigeria
Jazz Pharmaceuticals Soars with Promising HERIZON-GEA-01 Results - timothysykes.com
Jazz sells priority review voucher for $200 million - First Word Pharma
JAZZ: Sharpened rare disease focus, record growth, and pivotal zanidatamab results drive future milestones - TradingView — Track All Markets
JAZZ: Rare disease focus, record revenues, and zanidatamab's breakthrough in GEA drive future growth - TradingView — Track All Markets
JAZZ: Refined rare disease focus, strong 2025 results, and new launches drive future growth - TradingView — Track All Markets
Baird reiterates Underperform rating on Jazz Pharmaceuticals stock at $209 By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals PLC $JAZZ Holdings Lessened by Polaris Capital Management LLC - MarketBeat
Jazz Pharmaceuticals price target raised to $235 from $210 at Needham - Yahoo Finance
Jazz Pharmaceuticals stock price target raised to $263 from $247 at BofA - Investing.com Nigeria
Jazz Pharmaceuticals stock price target raised to $230 by Truist Securities - Investing.com Nigeria
Jazz Pharmaceuticals (JAZZ): Truist Securities Boosts Price Targ - GuruFocus
Truist Financial Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - MarketBeat
Jazz Pharmaceuticals plcExpects to meet 2025 revenue guidanceSEC filing - marketscreener.com
Jazz Pharmaceuticals PLCExpects To Meet 2025 Revenue GuidanceSEC Filing - TradingView — Track All Markets
Jazz Pharmaceuticals stock price target raised to $235 by Needham - Investing.com Nigeria
Boehringer and Jazz to test HER2-positive breast cancer combo therapy - Investing.com UK
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer - The Manila Times
What Analysts Are Saying About Jazz Pharmaceuticals Stock - Benzinga
Needham Raises Price Target for Jazz Pharmaceuticals (JAZZ) to $235 | JAZZ Stock News - GuruFocus
Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain - Yahoo Finance
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Weakness - Yahoo Finance
Is Jazz Pharmaceuticals (JAZZ) Still Attractive After 33% Share Price Gain This Year? - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval - MSN
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates - sharewise.com
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 - MarketBeat
Jazz Pharmaceuticals (JAZZ) Is Down 5.7% After Strong Ziihera Phase 3 DataHas The Bull Case Changed? - simplywall.st
Lecap Asset Management Ltd. Buys Shares of 6,319 Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by MassMutual Private Wealth & Trust FSB - MarketBeat
Robeco Institutional Asset Management B.V. Cuts Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Why Jazz Pharmaceuticals plc stock remains resilient2025 Earnings Impact & Daily Chart Pattern Signals - ulpravda.ru
What sentiment indicators say about Jazz Pharmaceuticals plc stockJuly 2025 WrapUp & Technical Confirmation Trade Alerts - ulpravda.ru
Jazz pharmaceuticals appoints Thomas Riga as chief business officer By Investing.com - Investing.com South Africa
Jazz pharmaceuticals appoints Thomas Riga as chief business officer - Investing.com
Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer - StreetInsider
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer - marketscreener.com
Should I hold or sell Jazz Pharmaceuticals plc stock in 2025Weekly Trend Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Positive Ziihera Phase 3 Gastroesophageal Cancer Results - simplywall.st
Is Jazz Pharmaceuticals plc stock positioned well for digital economyInstitutional Holding Changes & Free Stop-Loss Planning for Your Portfolio - ulpravda.ru
CX Institutional Has $8.06 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Why Is Jazz Pharmaceuticals Stock Trading Higher Today?Jazz Pharmaceuticals (NASDAQ:JAZZ) - Benzinga
Jazz’s Ziihera Stakes Claim As Frontline Choice In HER2+ Gastroesophageal Cancer - Citeline News & Insights
Jazz data not music to investors’ ears - The Pharma Letter
Jazz Pharmaceuticals stock shows promise with positive Phase 3 data By Investing.com - Investing.com Nigeria
Jazz Pharma stock falls after lowered full year guidance - MSN
Jazz Pharmaceuticals Plc (JAZZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):